BioXcel Therapeutics, Inc. (BTAI)
OTC: BTAI · Pharmaceutical Preparations · New Haven, CT · filing with the SEC since 2017
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
| Report filed | Mar 27, 2026 | Mar 28, 2025 | Mar 22, 2024 | Mar 16, 2023 | Mar 11, 2022 | Mar 12, 2021 | Mar 9, 2020 | Mar 12, 2019 | · |
| Revenue | 642 | 2,266 | 1,380 | 375 | · | · | · | · | · |
| Cost of revenue | 164 | 2,143 | 1,260 | 20 | · | · | · | · | · |
| Research and development | 30,251 | 30,435 | 84,326 | 91,239 | 52,708 | 57,995 | 25,797 | 14,558 | 2,690 |
| Selling, general and administrative | 20,494 | 34,492 | 83,413 | 68,761 | 54,227 | · | · | · | · |
| General and administrative | · | · | · | · | 54,227 | 24,302 | 7,804 | 5,404 | 1,847 |
| Total operating expenses | · | · | · | · | 106,935 | 82,297 | 33,601 | 19,962 | 4,537 |
| Total costs and expenses | 51,103 | 69,511 | 173,162 | 160,020 | 106,935 | · | · | · | · |
| Operating income | -50,461 | -67,245 | -171,782 | -159,645 | -106,935 | -82,297 | -33,601 | -19,962 | -4,537 |
| Interest expense | 15,332 | 14,662 | 11,941 | 7,353 | 40 | 27 | 20 | · | · |
| Interest and investment income | 1,066 | 2,602 | 5,649 | 2,528 | 44 | 155 | · | · | · |
| Interest income (expense), net | · | · | · | · | · | · | 633 | 692 | -2 |
| Other income (expense), net | -3,518 | 20,173 | 394 | -427 | · | · | · | · | · |
| Income tax expense | 0 | 0 | 0 | · | · | · | · | · | · |
| Net income including non-controlling interests | -69,897 | -59,599 | -179,053 | -165,757 | -106,931 | -82,169 | -32,968 | -19,270 | -4,539 |
| Net income | -69,897 | -59,599 | -179,053 | -165,757 | -106,931 | -82,169 | -32,968 | -19,270 | -4,539 |
| Earnings per share, basic | -5.73 | -23.51 | -98.33r | -94.72b | -64.80b | -60.64b | · | · | · |
| Earnings per share, diluted | -5.73 | -23.51 | -98.33r | -94.72b | -64.80b | -60.64b | · | · | · |
| Earnings per share, basic and diluted | · | · | · | · | · | -60.64b | -32.32b | -21.12b | -7.52b |
| Weighted average shares, basic | 12,208,000 | 2,535,000 | 1,821,000r | 1,750,938b | 1,648,312b | 1,355,188b | · | · | · |
| Weighted average shares, diluted | 12,208,000 | 2,535,000 | 1,821,000r | 1,750,938b | 1,648,312b | 1,355,188b | · | · | · |
| Weighted average shares, basic and diluted | · | · | · | · | · | 1,355,188b | 1,018,062rb | 910,722b | 605,313b |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Share counts and per-share figures are on the newest report's basis, after the 1-for-16 reverse split of Feb 2025.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxCost of revenue what it cost to make or buy what it sold
us-gaap:CostOfGoodsAndServicesSoldResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseSelling, general and administrative the cost of selling and of running the company
us-gaap:SellingGeneralAndAdministrativeExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesTotal costs and expenses every operating cost, the cost of revenue included
us-gaap:CostsAndExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseDebt
us-gaap:InterestExpenseInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestInterest income (expense), net interest earned less interest paid, outside the business
us-gaap:InterestIncomeExpenseNonoperatingNetOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted